Odawa — The National Advisory Board on Immunization states that it supports the urgent recommendation to extend the second dose of the COVID-19 vaccine for up to four months.
NACI experts felt that the vaccine supply was limited and that more people needed to be protected sooner, so the dosing interval should be extended from 3 weeks or 4 weeks to 16 weeks in early March. Was recommended.
NACI states that it still believes that follow-up recommendations based on further research on vaccines are.
“He helps provide direct protection to individuals and those around them, and may also help prevent their spread in the community,” said a report released Wednesday.
The Commission states that it does not expect the second dose to take as long as four months, based on Canada’s expected vaccine supply.
This recommendation was made in the same way that European and UK regulators updated their analysis of the threat posed by the Oxford-AstraZeneca vaccine from blood clots.
The European Medicines Agency says there is sufficient evidence to believe that certain blood clots are a rare side effect of the vaccine for a very small number of people, but due to the threat from COVID-19, the benefits of the vaccine are those. I believe it outweighs the risks of even greater.
“COVID-19 is a very serious illness with high hospitalization and mortality rates, and COVID still causes thousands of deaths across the EU,” said Emer Cooke, EMA’s Executive Director.
“This vaccine has proven to be very effective, preventing serious illness and hospitalization and saving lives.”
They still don’t know exactly what is causing the problem.
The EMA has added blood clots to the label as a rare side effect of the vaccine, but does not recommend withdrawing the vaccine from certain groups.
Blood clots occur in 1 in 100,000 people in Germany and 1 in 600,000 in the UK, Cook said.
Most cases are found in women under the age of 60, but she says that people of both genders and all ages had blood clots.
Canada stopped using the AstraZeneca vaccine in people under the age of 55 until further research on the vaccine was conducted. It is still unclear if that recommendation will change.